REG - Oncimmune Hldgs PLC - Appointment of new leadership team & board changes

Oncimmune HoldingsAnnouncement

12/07/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230712:nRSL6946Fa&default-theme=true

RNS Number : 6946F  Oncimmune Holdings PLC  12 July 2023

12 July 2023

 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

Appointment of new leadership team

 

Changes to the Board

 

Oncimmune Holdings plc (AIM: ONC.L), the leading autoantibody profiling
company to the pharmaceutical and biotechnology industry, is pleased to
announce changes to its leadership team and its Board of Directors.

 

As previously announced on 23 June 2023, following the divestment of Oncimmune
Limited, which now allows the Company to focus on its ImmunoINSIGHTS business,
Dr Adam M Hill stepped down as the Company's Chief Executive Officer and as a
director of the Company. Oncimmune is now pleased to announce that Martin
Gouldstone will be joining Oncimmune as its new Chief Executive Officer on 1
August 2023. Martin has over 25 years of experience in the life science
sector, including senior commercial roles at a major CRO and most recently as
Global Senior Vice President at Owkin Inc., an AI biotech company. Martin's
commercial experience and connections will be a valuable asset in driving the
Company's future business development activities. Martin will also join the
Company's Board of Directors and regulatory disclosures in relation to his
appointment as required under Schedule 2(g) of the AIM Rules for Companies can
be found at the foot of this announcement.

 

In addition, after more than five years as Oncimmune's Chief Financial
Officer, Matthew Hall has decided to leave his role at Oncimmune. Oncimmune
has recruited Martin Hudson to a new role of Finance Director, who will head
the Company's finance function and support the new Chief Executive Officer.
Martin is a CIMA qualified finance professional with over 19 years'
post-qualified international experience in large multinational and smaller
entrepreneurial environments. Martin has spent most of his career to date in
engineering and service companies, including more than seven years with the
McLaren Group and over four years at Williams Advanced Engineering. Martin
will be joining Oncimmune on 4 September 2023 and will be transitioning from
Matthew over the coming months.

 

Finally, after more than nine years with Oncimmune, Andrew Unitt will be
stepping down as an Independent Non-Executive Director of the Company and as
Chair of the Audit Committee on

30 September 2023. Andrew joined Oncimmune as non-executive director in 2014
and has chaired the Audit Committee since Oncimmune's IPO in 2016. The Company
has begun a search for a new Independent Non-Executive Director and Chair of
the Audit Committee.

 

Alistair Macdonald, Oncimmune's Chairman, said:

 

"On behalf of myself and the whole Board I would like to thank Andrew and
Matthew for their service to the Company over many years. I am very pleased to
welcome Martin Gouldstone and Martin Hudson to the leadership team. Martin
Gouldstone brings considerable experience in commercialising products and
services in the life science industry and will be leading our business
development efforts. With these changes to the leadership team, we believe
that Oncimmune is now poised to begin FY2024 with the right leadership and
resources to deliver on its plan for growth, which is based on our strong
intellectual property portfolio, our master services agreements with major
pharma companies and our recently announced long term relationship with
Freenome, Inc.

 

"Since our last announcement in June we have continued to engage with our
shareholders to understand their views on the Company's leadership and
direction. We will continue to engage all of our stakeholders as we move
forward, and we are excited to see the impact of a more focussed and
commercially orientated leadership team on the business."

 

Matthew Hall, Oncimmune's outgoing Chief Financial Officer, said:

 

"I would like to thank the Board for their support over the past five years,
as we transitioned the Company from a single asset diagnostic company to a
leading autoantibody profiling pharma services business. I wish the new
management team every success as they now capitalise on Oncimmune's industry
leading position."

 

Martin Gouldstone, Oncimmune's incoming Chief Executive Officer, said:

 

"I am delighted to be joining Oncimmune at such a pivotal time for its
business. I look forward to bringing my skills, experience and contacts in the
sector to drive the business development efforts and deliver for
stakeholders."

 

For further information:

Oncimmune Holdings plc

Ron Kirschner, Chief Executive Officer

contact@oncimmune.co.uk (mailto:contact@oncimmune.co.uk)

 

Singer Capital Markets (Nominated Adviser and Broker)

Phil Davies, Harry Gooden, George Tzimas, James Fischer

+44 (0)20 7496 3000

 

Zeus (Joint Broker)

Dominic King, Victoria Ayton, Dan Bate

+44 (0)20 3829 5000

+44 (0)20 3727 1000

 

About Oncimmune

 

Oncimmune is a specialist pharmaceutical services company, primarily focused
on the growing fields of immuno-oncology, autoimmune disease and infectious
diseases. Oncimmune has a contract discovery and development service business
whose ImmunoINSIGHTS platform delivers actionable insights into therapies to
the Company's pharmaceutical and biotech partners.

 

Our understanding of the immune system enables us to harness its sophisticated
response to disease to detect cancer earlier and to support the development of
better therapies. The key to improving cancer survival is early detection and
better selection for therapy. As a company, we are driven by our passion to
improve cancer survival and to give people extra time.

 

Oncimmune's ImmunoINSIGHTS platform enables life science organisations to
optimise drug development and delivery, leading to more effectively targeted
and safer treatments for patients. Oncimmune's ImmunoINSIGHTS service business
at its discovery research centre in Dortmund, Germany. The ImmunoINSIGHTS
business development team are based in the US and Europe.

 

For more information, visit www.oncimmune.com (http://www.oncimmune.com)

 

Regulatory Disclosures

The following information regarding the appointment of Martin Gouldstone, aged
56, is disclosed under Schedule 2(g) of the AIM Rules for Companies:

 Current Directorships                  Previous Directorships (within the last five years)
 ·    hVIVO plc                         ·    None

 ·    Novara Therapeutics Limited

 ·    Orthopaedic Research UK

 ·    Sempiternum Ltd

 

As at the date of this announcement, Martin Gouldstone does not hold any
ordinary shares in the Company.

Save as set out above there are no further disclosures pursuant to Rule 17 or
Schedule 2(g) of the AIM Rules for Companies in respect of the appointment of
Martin Gouldstone.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEALXFFSDDEFA